Spero Therapeutics, Inc. (SPRO)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 29/100 (MEDIUM), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 2.1% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
- Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript
- Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
- Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
- Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
- Innovent licenses IBI355 rights to Spero for up to $1.1bn
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Spero Therapeutics, Inc..
Full SPRO Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.